Gastrointestinal effects The most common side effects are gastrointestinal, driven primarily by the GLP-1 mediated slowing of gastric emptying
How to evaluate GLP-1 products With new GLP-1 branded products appearing weekly, having a systematic evaluation framework helps separate legitimate options from scams
Clinical evidence in T2DM management A wide range of clinical trials and research have been performed to assess the effectiveness, safety, and tolerability of short-acting against long-acting GLP-1 analogues in the treatment and management of T2DM and obesity
Combining the low doses with Noom's GLP-1 Companion support app "helps more patients stay on the treatment, experience the full health benefits of these medications, and make real progress in reducing obesity and overweight rates in the US," said the company's chief medical officer, Dr Jeffrey Egler
Regular monitoring ensures safe and effective treatment